NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.

In a research note, analyst Amit Bhalla said that he expects revenues to grow between 5 percent and 6 percent through fiscal 2014 with EPS growth of between 10 and 11 percent. He also noted Agilent's growing footprint in the life sciences, as well as its comparatively lighter exposure to the academic/government end markets and greater presence in the emerging markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.